AMG 301

Drug Profile

AMG 301

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Amgen
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 04 Jul 2017 Phase-II clinical trials in Migraine (Prevention) in Sweden (SC) (EudraCT2017-000630-57)
  • 01 Sep 2015 AMG 301 licensed to Novartis worldwide excluding, USA, Canada and Japan
  • 05 Aug 2015 Phase-I clinical trials in Migraine in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top